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What	are	the	indications	for	
meningococcal	vaccination?
evidence-based answer
routine vaccination with the 
meningococcal conjugate vaccine 
mCv4 (menactra) is indicated for all us 
adolescents entering high school and 
for college freshmen living in dormitories 
(strength of recommendation [sor]: B, 
based on observational studies). For 
convenience, mCv4 can be given at the 
11- to 12-year-old visit. 
 High-risk individuals (ages 2 and 
older) who should receive meningococcal 
vaccine (mCv4 or the unconjugated 
polysaccharide vaccine [mPsv4]) 
include those with terminal complement 
deficiencies, asplenia, or HIv, as well as 
military recruits, laboratory personnel 
exposed to aerosolized meningococci, 
and travelers to areas hyperendemic 
or epidemic for Neisseria meningitides 
(sor: c, based on consensus guidelines). 
routine vaccination of infants and toddlers 
with conjugate vaccine may be more cost-
effective than targeting adolescents, but 
conjugate meningococcal vaccine for this 
age group is not yet available in the us 
(sor: B, based on cohort studies). 
clinical commentary
The vaccine is available 
and efficacious—use it well
as a junior military medical officer, my first 
assignment was in san Diego, California 
near the former Naval Training Center (NTC). 
The NTC was the site of one of the last 
major outbreaks of meningococcal disease 
in a military barracks setting. I recall with 
alacrity the rapidity with which this disease 
overcomes its host, and the overwhelming 
morbidity (and mortality) the disease leaves 
behind if treatment is delayed. This is truly a 
“not-to-be-missed” diagnosis.
 The historical parallels between 
smallpox and meningococcal disease 
are striking. each is spread primarily by 
respiratory means, particularly in close 
quarters. While meningococcal disease 
is amenable to antibiotic treatment when 
recognized early (contrary to smallpox), the 
principles of high-risk “herd” immunization 
hold true for both conditions. By focusing 
on high-risk groups and adhering to aCIP 
recommendations, control of meningococcal 
disease is within the grasp of modern 
medical science. The vaccine is available. 
The vaccine is efficacious. use it well.
Mark Stephens, MD
uniformed services university, Bethesda, md
z	Evidence	summary
Two meningococcal vaccines are cur-
rently available in the US: tetravalent 
polysaccharide vaccine (MPSV4) and 
tetravalent polysaccharide-protein con-
jugate vaccine (MCV4). Both protect 
against serogroups A, C, Y, and W-135, 
but not against serogroup B, which is the 
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most prevalent. A vaccine for serogroup 
B is under development.
MPSV4 is licensed for ages 2 years 
and up, but its poor immunogenicity 
in infants, lack of memory and booster 
response, and relatively short duration of 
protection have restricted its use. MCV4 
is licensed for 11- to 55-year-olds and is 
the preferred vaccine in this age group, 
since it provides longer duration of 
immunity and reduces nasopharyngeal 
carriage.1 
Infants	and	freshman	
are	especially	vulnerable
Using active community surveillance 
from 1991 to 2002, Centers for Disease 
Control and Prevention (CDC) data2 
found annual rates of meningococcal dis-
ease in the US of 0.5 to 1.1 per 100,000. 
The highest rates were found in chil-
dren under age 2. Infants younger than 
12 months of age were especially vulner-
able (rate 9/100,000), with more than 
50% of cases caused by serogroup B. 
A 1998–1999 prospective surveil-
lance study3 including 50 state health 
departments and 231 college health 
centers identified 96 cases of meningococ-
cal disease in college students (incidence 
0.7/100,000). Freshmen living in dormito-
ries had an elevated risk of meningococ-
cal disease compared with other under-
graduates or nonstudents of the same age 
(incidence 5.1/100,000; adjusted relative 
risk=3.6 [95% confidence interval [CI], 
1.6–8.5). Sixty-eight percent had illness 
due to a vaccine-preventable serogroup.
Using CDC incidence data, a cost- 
effectiveness model4 compared hypo-
thetical vaccination strategies targeting 
US infants (3 doses), toddlers (1 dose), 
or 11-year-olds (1 dose). Routine MCV4 
vaccination of all 11-year-olds would 
prevent 270 cases and 36 deaths in this 
cohort over their next 22 years. For a 
toddler cohort, vaccination would pre-
vent 385 cases and 33 deaths; for infants, 
447 cases and 36 deaths. Conjugate me-
ningococcal vaccines for serogroups A 
and C have been tested and used in chil-
dren in other countries, and appear safe 
and effective, but are not yet available in 
the US. An application has been submit-
ted for FDA approval of MCV4 for 2- to 
10-year-olds. 
Who	should	get	vaccinated—and	when
Freshmen living 
in dormitories had 
an elevated risk 
of meningococcal 
disease compared 
with other  
undergraduates
tablE
TargeT PoPulaTion Vaccine TyPe
Children 2–10 years at increased risk* mPsv4†
adolescents 11–12 years mCv4
adolescents at high school entry or 15 years of age  mCv4 
    without prior vaccination
College freshmen planning to reside in dormitories mCv4‡
Patients ages 11–55 at increased risk* mCv4‡
Patients older than 55 years at increased risk* mPsv4
microbiologist, lab personnel exposed to N meningitides mCv4‡
military recruits mCv4‡
*  “Increased risk” is defined by terminal complement deficiency, anatomic or functional asplenia, travel to endemic 
areas, HIv infection (optional).
† may be repeated every 3 to 5 years if increased risk continues.
‡ mPsv4 is an acceptable alternative.
mPsv4, meningococcal polysaccharide vaccine; mCv4, meningococcal polysaccharide diphtheria toxoid conju-
gate vaccine.
adapted from Harrison, Clinical Microbiology Reviews 2006;1 Kimmel, Am Fam Physician 2005.9
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Herd	immunity	may	expand	
benefit	of	vaccination
A British study compared attack rates for 
meningococcal C disease in children from 
infancy to age 18 before and 1 to 2 years 
after the institution of a nationwide menin-
gococcal serogroup C conjugate vaccina-
tion. Vaccine coverage ranged from 66% 
(adolescents) to 87% (schoolchildren), 
and vaccine efficacy was 94% to 96%. 
Incidence of meningococcal C disease in 
the unvaccinated children also decreased 
by 52% to 67% (from 4.08/100,000 to 
1.36/100,000).5 
Vaccinating adolescents may be par-
ticularly helpful for building herd immu-
nity. A Norwegian study of nasopharyn-
geal meningococcal carriage among 943 
unimmunized individuals ages 2 months 
to 95 years found a carriage rate of 28% 
among 15- to 24-year-olds, compared 
with 9.6% overall.6
High hospitalization rates in US 
military recruits during 1964 to 1970 
(25.2/ 100,000) led to the development 
of the meningococcal polysaccharide vac-
cine. Since 1971, all new military recruits 
have received polysaccharide meningo-
coccal vaccine, and for the period 1990 
to 1998 the hospitalization rate for me-
ningococcal disease among active duty 
service members had decreased by 98% 
(to 0.51/100,000).7
Recommendations	from	others
The Advisory Committee on Immuniza-
tion Practices,2 American Academy of 
Pediatrics,8 American Academy of Family 
Physicians,9 and American College Associ-
ation10 recommendations are summarized 
in the TablE. Recommendations for vacci-
nation during meningococcal disease out-
breaks can be found at www.cdc.gov.2 n
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Vaccinating  
adolescents may 
be particularly 
helpful for building 
herd immunity
